Zug, Switzerland-based vVardis has secured a minority investment from Apollo Funds to support its next growth phase and commercial expansion.
The company’s Curodont technology is first and only commercially available non-invasive peptide-containing formulations clinically proven to treat tooth decay. The investment will fund the continued rollout of the Curodont suite, according to an April 27 news release from vVardis.
Curodont Repair Fluoride Plus is used by nearly 20% of general dental practices and has been used to treat about 3 million teeth in the U.S.
In 2025, vVardis closed on $35 million in financing in addition to landing a $50 million investment.
Haley Abivardi, DMD, and Goly Abivardi, DMD, the company’s founders and Co-CEOs will retain a substantial majority shareholding in vVardis, the release said.
